HK Stock MarketDetailed Quotes

01530 3SBIO

Watchlist
  • 6.800
  • +0.220+3.34%
Market Closed May 3 16:09 CST
16.58BMarket Cap9.70P/E (TTM)

About 3SBIO Company

Sansheng Pharmaceutical (the “Company” or “Sansheng Pharmaceutical”, together with its subsidiaries, collectively the “Group”) is a leading biotechnology company in the People's Republic of China (“China”). As a pioneer in the biotechnology industry in China, the Group has rich experience in R&D, production and marketing of biomedical products. The Group's core products include the various biopharmaceuticals Terbiao, recombinant human erythropotropin (“rhEPO”) products Ibio and Cyborg, Exipp, Ceptin, and the small molecule drug Mandy. Terbiao is the only commercialized recombinant human thrombocytopoietin (“rHTPO”) product in the world today. According to IQVIA1, in 2023, in terms of sales, Terbiao's share of the thrombocytopenia 2 treatment market in mainland China was 65.0%. With two rHepO products, the Group has been the leader in the RHepo market in mainland China for more than 20 years, accounting for a total market share of 42.2% in 2023. According to data from the Chinese Pharmaceutical Association (“CPA”), in 2023, in terms of sales, Mandy had a dominant market share of 72.6% of the minoxidil tincture market in mainland China. Exaipu is a tumor necrosis factor (“TNF”) inhibitor product and occupied 22.7% of the TNF market share in mainland China in 2023. The Group is also increasing products through internal research and development (“R&D”) and a number of external strategic collaborations to expand the field of treatment. At the same time, the Group adopted a strategic layout contract development and production operation (“CDMO”) business to increase the scale of revenue, and has been officially operating since December 2021. On December 31, 2023, out of the 29 products under development actively developed by the Group, 25 were developed as innovative drugs in mainland China. Among these products under development, 15 are antibodies, 7 are other biological products, and 7 are small molecule drugs. The Group has 13 hematology/oncology products under development; 11 products under development target autoimmune diseases (rheumatoid arthritis (“RA”), and other diseases, including intractable gout and ophthalmic diseases (such as retinal branch vein occlusion (“BRVO”)); 4 nephrology research products; and 1 dermatology product under development. The industries in which the Group operates are very attractive. Biotechnology is revolutionizing the pharmaceutical industry by addressing unmet pharmaceutical needs and providing innovative treatments for a wide range of human diseases. In mainland China, the biopharmaceutical industry has received strong support from the government and has been recognized as an important strategic emerging industry by the State Council of China. Strong government support and the increasing adoption of biopharmaceutical products by mainland Chinese physicians have contributed to the strong growth of the industry. The Group is expanding globally. In 2023, the Group's products were sold to 25 countries. In the long run, the Group aims to market its products in developed countries. The Group also cooperates with international partners to develop and market the Group's products under development, such as pegsiticase and anti-programmed death receptor 1 (“PD-1”) monoclonal antibodies (“monoclonal antibodies”). The Group aims to focus on research and development to provide innovative treatments for patients in mainland China and around the world. As of December 31, 2023, the Group had operating facilities in Shenyang, Shanghai, Hangzhou and Shenzhen (all in mainland China) and Como, Italy, with 5,412 employees. The Group's pharmaceutical products are promoted and sold in all provinces, autonomous regions and municipalities directly under the Central Government in mainland China, as well as in certain overseas countries and regions. For the year ended December 31, 2023 (the “reporting period”), the Group's nationwide distribution network sold the Group's products to more than 10,000 hospitals and medical institutions in mainland China.

Company Profile

Symbol01530
Company Name3SBIO
ISINKYG8875G1029
Listing DateJun 11, 2015
Issue Price9.10
Shares Offered606.10M share(s)
FoundedAug 9, 2006
Registered AddressCayman Islands
Chairmanjing lou
Secretaryshaojuan li
Audit InstitutionErnst & Young
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeCricket Square, Hutchins Drive PO Box 2681 Grand Cayman, KY1-1111 Cayman Islands
Head Office and Principal Place of Business5/F, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees5411
MarketHong Kong motherboard
Phone(024)25386218;(024)25386000
Fax(024)25817417;(024)25811821
Emailir@3sbio.com;webmaster@3Sbio.com
Business Sansheng Pharmaceutical is an investment holding company mainly engaged in the development, production, marketing and sale of pharmaceutical products. The company's main products include recombinant human thrombocytopoietin products, tumor necrosis factor alpha inhibitor products, and recombinant human rubiotropin. The products are sold under brands such as Terbiao, ISEP, IBIO, and SEBOR. The company sells its products in the domestic market and overseas markets such as Sri Lanka, the Dominican Republic and Thailand. The company's subsidiaries include Brainstorm Limited, Hong Kong Sansheng Medical Co., Ltd., and Shenyang Sansheng Pharmaceutical Co., Ltd. The company also engages in project management and consulting business through its subsidiaries.

Company Executives

  • Name
  • Position
  • Salary
  • jing lou
  • President,CEOs,Chairman,Executive Director,Chairman of the Nomination Committee
  • --
  • dongmei su
  • senior vice president,General Manager of Shenyang Sansheng,Executive Director,Authorized Representative
  • --
  • bin huang
  • Non-executive directors
  • --
  • tianruo pu
  • Independent Non-Executive Director,Chairman of the Audit Committee,Remuneration Committee Members,Nomination Committee Members
  • --
  • kaidi yang
  • Independent Non-Executive Director,Remuneration Committee Chairman,Audit Committee Members
  • --
  • zuyao huang
  • Independent Non-Executive Director,Audit Committee Members,Nomination Committee Members
  • --
  • weihong xiao
  • General Manager of Sansei Guoken
  • --
  • yanli liu
  • Deputy General Manager of Sansei Guoken,Board Secretary
  • --
  • yong xu
  • General Manager of Seipol Biotech,Director of Cypaul Biotech
  • --
  • shaojuan li
  • Company Secretary,Authorized Representative
  • --
  • xiang he
  • chief financial officer
  • --
  • dan zhang
  • Independent Non-Executive Director,Remuneration Committee Members
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg